SEHK:2186Pharmaceuticals
A Look At Luye Pharma Group (SEHK:2186) Valuation As LY03020 Enters Phase II For Schizophrenia
Luye Pharma Group (SEHK:2186) has drawn fresh attention after reporting the first patient enrollment in a Phase II trial in China for LY03020, a dual TAAR1 and 5-HT2CR agonist targeting schizophrenia.
See our latest analysis for Luye Pharma Group.
The LY03020 trial update comes as Luye Pharma Group’s share price sits at HK$2.89, with a 30-day share price return of 18.93% contrasting with a 90-day share price decline of 3.99%. The 1-year total shareholder return of 55.38% stands against a...